Stocks · Health care · Biological Products, (No Diagnostic Substances)

Beam Therapeutics Inc.

BEAM Clue Score48
United States Fiscal year ends December CIK 0001745999 Results filed 3 Nov 2026

What the insiders did Net selling

Insider
Date
Role
Action
Shares
Price
Amount
John M. Evans
16 Oct 2026
CEO
Sold after exercise
25,000
$23.98
$599.60K
John M. Evans
15 Oct 2026
CEO
Sold after exercise
25,000
$23.57
$589.15K
John M. Evans
30 Jun 2026
CEO
Sold after exercise
1,900
$34.84
$66.20K
John M. Evans
30 Jun 2026
CEO
Sold after exercise
23,100
$34.26
$791.48K
John M. Evans
29 Jun 2026
CEO
Sold after exercise
11,579
$35.91
$415.82K
John M. Evans
29 Jun 2026
CEO
Sold after exercise
13,421
$35.13
$471.53K
John M. Evans
31 Mar 2026
CEO
Sold after exercise
25,000
$22.76
$569.09K
John M. Evans
30 Mar 2026
CEO
Sold after exercise
25,000
$22.37
$559.23K
Giuseppe Ciaramella
24 Feb 2026
President
Sold after exercise
35,000
$32.00
$1.12M
John M. Evans
30 Jan 2026
CEO
Sold after exercise
2,906
$29.00
$84.27K
John M. Evans
30 Jan 2026
CEO
Sold after exercise
22,094
$28.27
$624.67K
John M. Evans
29 Jan 2026
CEO
Sold after exercise
8,667
$29.74
$257.78K
John M. Evans
29 Jan 2026
CEO
Sold after exercise
16,333
$29.19
$476.80K

What was left out

Form 4 filings counted 39
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 16
Sales straight out of an exercise 13
Sales at will 2
Transactions with no price 0
Shares from compensation/vesting 639,912
History held since 11 Feb 2020